ATP12A promotes mucus dysfunction during Type 2 airway inflammation.

Area of Science:

• Pulmonary Medicine
• Immunology
• Cell Biology

Background:

• Allergic airway diseases cause morbidity via impaired mucociliary clearance.
• The exact mechanisms of mucus dysfunction in these conditions remain unclear.
• Interleukin 13 (IL-13) is a key mediator of Type 2 (T2) inflammation, affecting airway epithelium.

Purpose of the Study:

• To investigate the mechanism by which IL-13 causes mucus dysfunction.
• To determine the role of airway surface liquid (ASL) viscosity in IL-13-induced mucus dysfunction.
• To identify potential therapeutic targets for improving mucus clearance.

Main Methods:

• Primary human bronchial epithelial cells were cultured.
• IL-13 treatment was applied to assess effects on ASL viscosity and pH.
• ATP12A (a non-gastric H+/K+-ATPase) function was modulated via knockdown or inhibition.
• Rheological properties of ASL were measured.

Main Results:

• IL-13 significantly increased ASL viscosity in cultured human bronchial epithelial cells.
• Increased ASL viscosity led to inhibited mucus clearance.
• ATP12A was required for the IL-13-dependent increase in ASL viscosity.
• ATP12A inhibition prevented increased ASL viscosity without altering ASL pH.

Conclusions:

• IL-13 induces airway mucus dysfunction by increasing ASL viscosity through ATP12A.
• ATP12A plays a critical role in promoting mucus dysfunction in T2 inflammatory airway diseases.
• ATP12A represents a potential novel therapeutic target to enhance mucus clearance.